

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A cell line which expresses on the cell surface Thomsen-Friedenreich antigen (TF), mucin 1 (MUC1), and glycophorin.
2. (Cancelled)
3. (Previously presented) The cell line of claim 1 which is selected from the group consisting of
 - (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606;
 - (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and
 - (c) subclones of (a) or (b) which express on the cell surface TF, MUC1, and glycophorin.
4. (Cancelled)
5. (Previously presented) The cell line of claim 1, comprising a vector which comprises a nucleic acid molecule.
6. (Original) The cell line of claim 5, wherein said nucleic acid molecule encodes at least one polypeptide of a polypeptide selected from the group consisting of a cytokine, MHC class I molecule, MHC class II molecule and costimulatory molecule, T cell epitope or multimers thereof, tumour antigen, hormone, sexual

hormone, adjuvant, antibody or other molecules or fragments thereof having biological activity or any combination thereof.

7-10. (Cancelled)

11. (Currently amended) A composition comprising

(a)—a cell line which expresses on the cell surface TF, MUC1, and glycoporphin;

~~(b)—a lysate, a molecule, or a mixture of molecules obtained from the cell line of (a);~~

~~(c)—dendritic cells loaded with the lysate, the molecule, or the mixture of molecules of (b); or~~

~~(d)—dendritic cells co-incubated or fused with the cells of (a).~~

12. (Previously presented) The composition of claim 11, which is a pharmaceutical or vaccine composition.

13-22. (Cancelled)

23. (Previously presented) The cell line of claim 1, wherein the glycoporphin is asialoglycoporphin.

24. (Currently amended) The cell line of claim 1, wherein the MUC1 is tumor-associated MUC1 (TA-MUC1).